BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Boston Pharmaceuticals Appoints Dr. Craig T. Basson, M.D., Ph.D., as Chief Medical Officer

  Boston Pharmaceuticals today announced the appointment of Dr. Craig T. Basson, M.D., Ph.D., as Chief Medical Officer.

  February 3, 2020

   · 

  3 min read
• Business

  IMIDomics and Gossamer Bio Enter into a Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases

  IMIDomics S.L. announced they have entered into a strategic collaboration with Gossamer Bio, Inc., to advance the discovery and development of novel treatments to address patients with Immune-Mediated Inflammatory Diseases.

  February 3, 2020

   · 

  2 min read
• Business

  Avacta and Daewoong Agree Collaboration and License Agreement with AffyXell Therapeutics

  License agreement to utilise Affimer proteins in next generation cell and gene therapies

  February 3, 2020

   · 

  3 min read
• Job Trends

  Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

  Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type

  February 3, 2020

   · 

  11 min read
• Policy

  Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDA

  Mesoblast Limited announced that it has submitted its completed Biologics License Application to the United States Food and Drug Administration for Ryoncil™, its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease.

  February 3, 2020

   · 

  5 min read
• Deals

  Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Stock option award offered as inducement to Ivor Macleod, new Chief Financial Officer of Athersys

  February 3, 2020

   · 

  2 min read
• Business

  Amir Shojaei, PharmD, PhD, to Join iVeena Board of Directors

  iVeena Delivery Systems, Inc., a clinical stage biopharmaceutical company with developmental products in cornea and cataract, announces the appointment of Dr. Amir Shojaei to the iVeena Board of Directors.

  February 3, 2020

   · 

  2 min read
• Biotech Beach

  AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus

  Currently there are no therapies or vaccines for patients infected with 2019-nCoV coronavirus around the world.

  February 3, 2020

   · 

  1 min read
• Business

  Centene Appoints Jennifer Gilligan, Senior Vice President, Investor Relations

  Centene Corporation announced the appointment of Jennifer Gilligan to Senior Vice President, Investor Relations.

  February 3, 2020

   · 

  9 min read
• Job Trends

  ALPHA PRO TECH INCREASES N-95 FACE MASK PRODUCTION IN RESPONSE TO WUHAN CORONAVIRUS (2019-nCoV) OUTBREAKPRODUCTION INCREASED TO RESPOND TO SIGNIFICANT DEMAND

  Alpha Pro Tech, Ltd. (NYSE American: APT), today announced that the company is exponentially ramping up production of its N-95 Particulate Respirator face mask in response to a significant increase in customer demand and level of orders resulting from the outbreak of the novel Wuhan coronavirus

  February 3, 2020

   · 

  4 min read